SCHEMBL21501233

SCHEMBL21501233

CC(Cl)[C@@H](C)Oc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 4/20 0.43
MTNR1B P49286 4/20 0.43
KDM4E B2RXH2 1/20 0.40
CA4 P22748 1/20 0.40
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
PKM P14618 1/20 0.38
CYP2C19 P33261 1/20 0.38
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
MAOA P21397 2/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
MAOB P27338 1/20 0.38
NISCH Q9Y2I1 1/20 0.38
LTA4H P09960 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22986087 1.00 MTNR1A (0.43) MTNR1AMTNR1BKDM4ECA4LMNA
SCHEMBL1453272 0.85 CA4 (0.48) MTNR1AMTNR1BKDM4ECA4LMNA
SCHEMBL15277309 0.82 CA4 (0.42) MTNR1AMTNR1BKDM4ECA4LMNA
SCHEMBL16807836 0.81 MTNR1A (0.43) MTNR1AMTNR1BKDM4ECA4LMNA
SCHEMBL25882988 0.80 CA4 (0.43) MTNR1AMTNR1BKDM4ECA4LMNA
SCHEMBL941113 0.80 CA4 (0.43) MTNR1AMTNR1BKDM4ECA4LMNA
SCHEMBL2001545 0.80 CA4 (0.43) MTNR1AMTNR1BKDM4ECA4LMNA
SCHEMBL15634617 0.77 MTNR1A (0.41) MTNR1AMTNR1BKDM4ECA4LMNA
SCHEMBL9541523 0.76 MTNR1A (0.43) MTNR1AMTNR1BKDM4ECA4LMNA
SCHEMBL25325632 0.76 LMNA (0.48) MTNR1AMTNR1BKDM4ECA4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190322676-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARM INC (US) 2019-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322676-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE UGCG, MAN2B1, GBA1 MTNR1A 1873/4885MTNR1B 1333/4885KDM4E 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.